Nektar Therapeutics Starts Clinical Study

March 27, 2017

Nektar Therapeutics said it has begun dosing in a phase 1 clinical study evaluating NKTR-358, the company’s new biologic therapy, which is being developed to treat a wide range of auto-immune diseases and inflammatory disorders.

NKTR-358 selectively stimulates the growth and activation of regulatory T cells in the body in order to restore the body’s self-tolerance mechanisms. The study will evaluate single-ascending doses of NKTR-358 in approximately 50 healthy subjects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Stephen Holmes

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: